Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EORTC CLTF 2021 | The future of immuno-oncology

Jérôme Galon • 14 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Jérôme Galon, MD, PhD, Inserm, Paris, France, talks on the future of immuno-oncology, highlighting the importance of immunotherapies in precision medicine and the recently developed Immunoscore® assay. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Jérôme Galon

The prognostic value of memory T-cell reactions 2:25
The prognostic value of memory T-cell reactions
Jérôme Galon • 14 Oct 2021
The cancer immune contexture 1:20
The cancer immune contexture
Jérôme Galon • 14 Oct 2021
Immunoscore®: classifying patients based on immune characteristics 1:36
Immunoscore®: classifying patients based on immune characteristics
Jérôme Galon • 14 Oct 2021
Immune escape mechanisms in human cancers 1:44
Immune escape mechanisms in human cancers
Jérôme Galon • 14 Oct 2021

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals